Singh Nidhi, Das Prasenjit, Gupta Surabhi, Sachdev Vikas, Srivasatava Siddhartha, Datta Gupta Siddhartha, Pandey Ravindra Mohan, Sahni Peush, Chauhan Shyam S, Saraya Anoop
Nidhi Singh, Surabhi Gupta, Vikas Sachdev, Siddhartha Srivasatava, Anoop Saraya, Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi 110029, India.
World J Gastroenterol. 2014 Dec 14;20(46):17532-40. doi: 10.3748/wjg.v20.i46.17532.
To assess the prognostic significance of cathepsin L, a cysteine protease that degrades the peri-tumoral tissue, in patients with pancreatic cancer.
Plasma samples from 127 pancreatic cancer patients were analyzed for cathepsin L levels by ELISA. Out of these patients, 25 underwent surgery and their paraffin-embedded tissue was analyzed for cathepsin L expression by immunohistochemistry. Survival of patients and clinicopathological parameters was correlated with cathepsin L expression in plasma and tissue using appropriate statistical analysis.
The mean (± SD) cathepsin L in plasma samples of pancreatic cancer patients was 5.98 ± 2.5 ng/mL that was significantly higher compared to the levels in healthy controls (3.83 ± 0.45) or chronic pancreatitis patients (3.97 ± 1.06). Using ROC curve, a cut-off level of 5.0 ng/mL was decided for survival analysis. Elevated plasma levels of cathepsin L were found to be associated with poor prognosis (P = 0.01) in multivariate analysis. The plasma levels of the protease decreased after surgery. Though no significant correlation was seen between plasma and tissue expression of this protease, a trend did emerge that high cathepsin L expression in tissue correlated with its high levels in plasma.
Cathepsin L levels in plasma of pancreatic cancer patients may be used as a potential prognostic marker for the disease.
评估组织蛋白酶L（一种可降解肿瘤周围组织的半胱氨酸蛋白酶）在胰腺癌患者中的预后意义。
采用酶联免疫吸附测定法（ELISA）分析127例胰腺癌患者血浆样本中的组织蛋白酶L水平。其中25例患者接受了手术，其石蜡包埋组织通过免疫组织化学法分析组织蛋白酶L的表达情况。使用适当的统计分析方法，将患者的生存率及临床病理参数与血浆和组织中组织蛋白酶L的表达进行关联分析。
胰腺癌患者血浆样本中组织蛋白酶L的平均水平（±标准差）为5.98±2.5 ng/mL，显著高于健康对照组（3.83±0.45）或慢性胰腺炎患者（3.97±1.06）。通过ROC曲线分析，确定用于生存分析的临界值为5.0 ng/mL。多因素分析发现，血浆中组织蛋白酶L水平升高与预后不良相关（P = 0.01）。术后该蛋白酶的血浆水平下降。虽然该蛋白酶的血浆和组织表达之间未发现显著相关性，但出现了一种趋势，即组织中组织蛋白酶L高表达与其血浆中的高水平相关。
胰腺癌患者血浆中的组织蛋白酶L水平可作为该疾病潜在的预后标志物。
